Valor20212022202320242025TTMGastos comerciales, generales y administrativos537.8 M514.7 M572.9 M560 M537.6 M537.6 MInvestigación y desarrollo81.9 M85.4 M88.7 M113.4 M106.8 M106.8 MBeneficio operativo-190.5 M-140.6 M-257.4 M-123.5 M-387.2 M-387.2 MTotal de ingresos no operativos133.4 M0-4.8 M0-7.9 M-7.9 MGastos por intereses, netos de intereses capitalizados6.6 M3.2 M2.9 M2.8 M10.5 M10.5 MIngresos no operativos, una vez deducidos los gastos por intereses-12.5 M-3.8 M-3.3 M-3.9 M-19.2 M-19.2 MIngresos/gastos extraordinarios139.3 M600 K-4.4 M1.1 M800 K800 KBeneficio antes de impuestos-57.1 M-140.6 M-262.2 M-123.5 M-395.1 M-395.1 MParticipación en los beneficios——————Impuestos-29.9 M-28.6 M1.1 M3.8 M-29.2 M-29.2 MParticipación minoritaria00————Otros ingresos/gastos después de impuestos——————Beneficio neto antes de actividades interrumpidas-27.2 M-112 M-263.3 M-127.3 M-365.9 M-365.9 MOperaciones suspendidas——————Beneficio neto-27.2 M-112 M-263.3 M-127.3 M-365.9 M-365.9 MAjuste por dilución——————Dividendos de las acciones preferentes——————Beneficio neto diluido atribuible a los accionistas-27.2 M-112 M-263.3 M-127.3 M-365.9 M-365.9 MBeneficio básico por acción-0.35-1.39-3.18-1.41-3.95-3.95Beneficio por acción diluido-0.35-1.39-3.18-1.41-3.95-3.95Número medio de acciones ordinarias78 M80.6 M82.8 M90.6 M92.6 M369.6 MAcciones diluidas78 M80.6 M82.8 M90.6 M92.6 M369.6 MEBITDA-127.7 M-87.9 M-195.5 M-61.9 M-333 M-306.3 MEBIT-190.5 M-140.6 M-257.4 M-123.5 M-387.2 M-387.2 MCosto de los ingresos11.7 M00252.2 M247.9 M247.9 MOtros costes de producción11.7 M00———Amortización y depreciación (flujo de caja)62.8 M52.7 M61.9 M61.6 M54.2 M80.9 M
Myriad Genetics Inc
Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to a particular drug therapy, assess a patient's risk of disease progression and disease recurrence, and measure disease activity.